The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort.
Damotte D, Warren S, Arrondeau J, Boudou-Rouquette P, Mansuet-Lupo A, Biton J, Ouakrim H, Alifano M, Gervais C, Bellesoeur A, Kramkimel N, Tlemsani C, Burroni B, Duche A, Letourneur F, Si H, Halpin R, Creasy T, Herbst R, Ren X, Morel P, Cesano A, Goldwasser F, Leroy K.
Damotte D, et al. Among authors: alifano m.
J Transl Med. 2019 Nov 4;17(1):357. doi: 10.1186/s12967-019-2100-3.
J Transl Med. 2019.
PMID: 31684954
Free PMC article.